Czech Republic

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05

BMI View: It is clear that the Czech Republic pharmaceutical and healthcare market will be under intense pressure in 2012, the combination of drug policy reforms and a weak economic... 2012-02-02

BMI View: A worsening economic outlook, combined with comments from the Czech health minister Leos Heger in mid-November 2011, indicate that public funding for healthcare services will... 2011-11-17

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: The Czech Republic's healthcare reforms will provide additional funding for medical provision, but the majority of new resources will be required for higher salaries and offsetting... 2011-09-09

BMI View: While 2012 is set to be an unusually difficult year for drugmakers in Central Europe, we maintain our view that the long-term growth potential of this region is favourable,... 2011-08-25

BMI View: The Czech Republic's disease and drug consumption profile illustrates a considerable gap between this market and Western Europe, suggesting that the population's demand for... 2011-07-07

BMI View: While many innovative pharmaceutical firms have identified pricing policies and weaknesses in Turkey's IP framework as key challenges that will continue to deter further capital... 2011-06-29

BMI View: Increases in the VAT paid on medicines and healthcare services in the Czech Republic will lead to moderately higher prices and reduce affordability. While spending on reimbursed... 2011-03-24